Author:
Ma Yuedan,Shi Xiaoxia,Sznajder Kristin K.,Zhao Yue,Wan Quan,Chai Peipei,Yang Xiaoshi
Abstract
Introduction: Depression is the leading cause of disability worldwide and has become a health issue of global concern. Based on the “System of Health Accounts 2011” (SHA 2011) for patients with depression, this paper studies the changes in the current curative expenditure (CCE) of outpatient depression in Liaoning Province, China, and provides policy recommendations.Method: A stratified multistage random sample of 56,994 patients with depression included from 1,227 healthcare facilities in Liaoning Province were included. The significance of differences in variables within groups was analyzed by univariate analysis (including descriptive statistics analysis, Mann-Whitney U test and Kruskal–Wallis H test), and factors influencing depression outpatient CCE were analyzed by multiple linear regression analysis and constructing structural equation models (SEM).Results: The CCE of outpatient depression was ranging from CNY 75.57 million to CNY 100.53 million in 2015–2020, with the highest of CNY 100.53 million in 2018, CNY 103.28 million in 2019. Medical expenditures are mainly concentrated in general hospitals and provincial healthcare institutions, accounting for about 90% of all provincial scope expenditures. The multiple regression results show that provincial healthcare institutions, purchase of drug, select medical treatment for depression, general hospitals and urban employees’ health insurance are the main influencing factors for depression outpatient CCE. The results of SEM show that insurance status negative impact outpatient expenditure.Conclusion: Health insurance is an important factor in equitable access to healthcare resources for patients, and medication expenditure is the influential factor affecting the high expenditure of outpatient clinics. It is of great importance to reduce the medical burden of patients by increasing the coverage of medical insurance, increasing the proportion of bills that are eligible for reimbursement, and improving the system by guaranteeing the supply of psychotropic medication.
Reference47 articles.
1. Depression treatment expenditures for adults in the USA: a systematic review;Breslow;Curr. Psychiatry Rep.,2019
2. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Collaborators;Lancet,2018
3. Prevalence and development of psychiatric disorders in childhood and adolescence;Costello;Arch. Gen. Psychiatry,2003
4. Antidepressant use and expenditure in the treatment of patients with depression: evidence from China urban medical claims data;Ding;J. Affect Disord.,2022
5. Trends in costs of depression in adults with diabetes in the United States: medical expenditure panel survey, 2004-2011;Egede;J. Gen. Intern Med.,2016